SLC5A2 and type 2 diabetes mellitus: Among patients who presented with a UTI, 25.3% (57/225) were treated with SGLT2 inhibitors, while among patients without UTIs, 20.9% (191/914) were using SGLT2 inhibitors for the treatment of T2D (OR 1.28; 95% CI: 0.91–1.80, p = 0.1).